BB-1712 IND approved by China NMPA

BB-1712 IND approved by US FDA

Phase II clinical data of BB-1701 presented at ESMO 2024

BB-1701 oral presentation at 3rd World ADC Asia

Phase I clinical data of BB-1701 presented at ASCO 2024

Co-founder, Chairman, CEO

◆　Ph.D. in Chemistry at Rutgers, the State University of New Jersey, and B.S. in Chemistry at the University of Science and Technology of China.

◆　Over 30 years of experience in biopharmaceutical development and commercialization in multi-national biotech and pharmaceutical companies 

◆　Served in CMC development at Novavax, Medimmune-AstraZeneca, Bristol-Myers Squibb, and Johnson & Johnson in US

◆　Contributed to the development of over 40 antibodies and vaccine products, including therapeutic monoclonal antibodies, bispecific antibodies, ADCs, recombinant proteins, and recombinant protein and virus vaccine, of which 9 were approved to the market.

◆　Contributed to monoclonal antibody guidelines for the United States Pharmacopoeia

◆　Former president of American Chinese Biopharmaceutical Association (CBA)

◆　Dozens of patents, 80+ journal publications, patents, and book chapters, scientific abstracts, presentations, and short courses at national and international conferences.

◆　Distinguished scientific professional with comprehensive academic credentials: Ph.D. in Microbiology and Molecular Genetics from Rutgers University, USA; M.S. and B.S. in Genetics and Biochemistry from Fudan University, China

◆　Over 30 years of pioneering research experience in targeted therapy and immunotherapy across leading biotech and multinational pharmaceutical companies, including MORPHOTEK/EISAI, Johnson & Johnson, Roche, and Bristol-Myers Squibb

◆　Senior expert and project leader in the field of immunology and immune-oncology, skilled in executing full R&D program lifecycle—from initial target validation and conceptual design to delivering IND-enabling research strategies

◆　Successfully led multiple innovative drug development initiatives, completed three national fund-sponsored projects, and generated an extensive portfolio of patents

◆　Prolific researcher with significant publications in prestigious scientific journals including Cell, PNAS, and Nature, with numerous presentations at national and international conferences

Co-founder, CSO